In the fiscal year ending on June 30 of the previous year, Square Pharmaceuticals achieved a year-on-year profit growth of 4.53 percent, reaching Tk 1,898 crore. According to the company’s annual report, it had earned a profit of Tk 1,815 crore in the preceding fiscal year. Consequently, the consolidated earnings per share for the fiscal year 2022-23 rose to Tk 21.41, compared to Tk 20.48 in the previous year.
The consolidated net asset value per share increased from Tk 104.92 to Tk 113.39, while the net operating cash flow per share decreased from Tk 13.93 to Tk 9.17, as reported in the annual statement. Square Pharmaceuticals, a Bangladeshi multinational pharmaceutical company, reported consolidated net revenue of Tk 6,274.7 crore for the fiscal year 2022-23, marking an 8.9 percent increase over the previous year.
Square Pharmaceuticals operates as the parent company of a group of four entities, with subsidiaries including Square Lifesciences, Square Pharmaceuticals Kenya EPZ, and Samson Pharma Inc, Philippines. Zahangir Alam, the Chief Financial Officer of Square Pharmaceuticals, attributed the company’s success to its extensive product range, long-standing presence in the market, and widespread acceptance among healthcare professionals.
Alam highlighted that Square Pharmaceuticals benefits from its strong reputation, resulting in lower marketing costs compared to competitors. Additionally, the company has minimal financing costs due to its low loan exposure. While Square Pharmaceuticals experienced notable profit growth, Alam mentioned that it could have been even higher if inter-company profits, particularly from Square Textile, had been greater.
Square Pharmaceuticals and its subsidiaries operate in the pharmaceutical industry, serving global markets. The company’s associate entities are involved in various sectors, including yarn manufacturing, knitting, dyeing, garment manufacturing, hospitals, and diagnostic and pathological laboratories.
